Clinical Trials
11
Trial Phases
2 Phases
Drug Approvals
1
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (7 trials with phase data)• Click on a phase to view related trials
A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High-Risk Patients With Hypertriglyceridemia and on Statin
- Conditions
- Cardiovascular Diseases
- Interventions
- First Posted Date
- 2011-12-15
- Last Posted Date
- 2022-04-14
- Lead Sponsor
- Amarin Pharma Inc.
- Target Recruit Count
- 8179
- Registration Number
- NCT01492361
- Locations
- 🇺🇦
Amarin Investigational Site, Zaporizhzhia, Ukraine
Effect of AMR101 (Ethyl Icosapentate) on Triglyceride (Tg) Levels in Patients on Statins With High Tg Levels (≥ 200 and < 500 mg/dL)
- Conditions
- Hypertriglyceridemia
- Interventions
- Drug: PlaceboDrug: AMR101 (ethyl icosapentate) - 2 g/dayDrug: AMR101 (ethyl icosapentate) - 4 g/day
- First Posted Date
- 2010-01-13
- Last Posted Date
- 2022-04-25
- Lead Sponsor
- Amarin Pharma Inc.
- Target Recruit Count
- 702
- Registration Number
- NCT01047501
- Locations
- 🇺🇸
Amarin Investigational Site, Wauwatosa, Wisconsin, United States
Efficacy and Safety of AMR101 (Ethyl Icosapentate) in Patients With Fasting Triglyceride (Tg) Levels ≥ 500 and ≤ 2000 mg/dL
- Conditions
- Hypertriglyceridemia
- Interventions
- Drug: AMR101 (ethyl icosapentate) - 2 g/dayDrug: AMR101 (ethyl icosapentate) - 4 g/dayDrug: Placebo
- First Posted Date
- 2010-01-13
- Last Posted Date
- 2022-04-25
- Lead Sponsor
- Amarin Pharma Inc.
- Target Recruit Count
- 229
- Registration Number
- NCT01047683
- Locations
- 🇺🇦
Amarin Investigational Site, Odessa, Ukraine
News
Amarin to Present New REDUCE-IT Analyses and EPA Mechanistic Data at ESC Congress 2025
Amarin Corporation will present new post hoc analyses from the REDUCE-IT trial and mechanistic studies of eicosapentaenoic acid (EPA) at the European Society of Cardiology Congress 2025 in Madrid, Spain.
HLS Therapeutics Secures Nova Scotia Reimbursement for Vascepa, Expanding Cardiovascular Drug Access to 95% of Eligible Canadians
HLS Therapeutics has secured a Product Listing Agreement with Nova Scotia Pharmacare for Vascepa (icosapent ethyl) reimbursement, effective July 1, 2025.
Recordati Secures Exclusive European Rights to Cardiovascular Drug Vazkepa in $175 Million Deal with Amarin
Recordati has acquired exclusive licensing and supply rights to commercialize Vazkepa (icosapent ethyl) across 59 European countries in a deal worth up to $175 million with Amarin.